CN116056702B - 治疗高胆固醇血症的方法 - Google Patents

治疗高胆固醇血症的方法

Info

Publication number
CN116056702B
CN116056702B CN202180050829.0A CN202180050829A CN116056702B CN 116056702 B CN116056702 B CN 116056702B CN 202180050829 A CN202180050829 A CN 202180050829A CN 116056702 B CN116056702 B CN 116056702B
Authority
CN
China
Prior art keywords
cholesterol
compound
disease
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180050829.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN116056702A (zh
Inventor
S·贝拉丘
E·卡西尔麦克法兰
Z·邵
H-H·蔡
R·魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Massachusetts Co ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN116056702A publication Critical patent/CN116056702A/zh
Application granted granted Critical
Publication of CN116056702B publication Critical patent/CN116056702B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180050829.0A 2020-08-19 2021-08-19 治疗高胆固醇血症的方法 Active CN116056702B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067786P 2020-08-19 2020-08-19
US63/067,786 2020-08-19
PCT/US2021/046591 WO2022040371A1 (en) 2020-08-19 2021-08-19 Methods for treating hypercholesterolemia

Publications (2)

Publication Number Publication Date
CN116056702A CN116056702A (zh) 2023-05-02
CN116056702B true CN116056702B (zh) 2026-01-23

Family

ID=77693631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050829.0A Active CN116056702B (zh) 2020-08-19 2021-08-19 治疗高胆固醇血症的方法

Country Status (5)

Country Link
US (1) US12472171B2 (cg-RX-API-DMAC10.html)
EP (1) EP4199928B1 (cg-RX-API-DMAC10.html)
JP (1) JP7824930B2 (cg-RX-API-DMAC10.html)
CN (1) CN116056702B (cg-RX-API-DMAC10.html)
WO (1) WO2022040371A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096421A (zh) * 2020-08-19 2023-05-09 渤健马萨诸塞州股份有限公司 用于治疗缓解型多发性硬化的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053568A1 (en) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
CN106278999B (zh) * 2011-02-07 2019-10-25 比奥根Ma公司 S1p调节剂
BR112015001613B1 (pt) * 2012-07-27 2021-02-23 Biogen Ma Inc compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096421A (zh) * 2020-08-19 2023-05-09 渤健马萨诸塞州股份有限公司 用于治疗缓解型多发性硬化的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Development of an Early Phase Process for a Potent Oligodendrocyte Precursor Cell Differentiator;Donald G. Walker等;Organic Process Research & Development;20240209;2203–2212 *

Also Published As

Publication number Publication date
US12472171B2 (en) 2025-11-18
US20230310405A1 (en) 2023-10-05
CN116056702A (zh) 2023-05-02
JP2023538066A (ja) 2023-09-06
JP7824930B2 (ja) 2026-03-05
WO2022040371A1 (en) 2022-02-24
EP4199928A1 (en) 2023-06-28
EP4199928B1 (en) 2025-11-26

Similar Documents

Publication Publication Date Title
Ito et al. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
JP7306791B2 (ja) 併用療法のための医薬組成物
JP2023178518A (ja) シクロデキストリンを使用するための方法
CN116056702A (zh) 治疗高胆固醇血症的方法
UA75614C2 (uk) Спосіб лікування гетерозиготної родинної гіперхолестеринемії розувастатином (zd-4522)
Riccio et al. Nutritional treatment in chronic kidney disease: the concept of nephroprotection
Farmer et al. Antihyperlipidaemic agents: drug interactions of clinical significance
Mitch et al. Mechanisms activated by kidney disease and the loss of muscle mass
WO2010036822A1 (en) Patient populations and treatment methods
US20230067847A1 (en) Combination of berberine and derivatives thereof, and vitamin b12
US20230390270A1 (en) Methods for treating remitting multiple sclerosis
Lee et al. Pregnancy facilitates maternal liver regeneration after partial hepatectomy
Jessurun et al. Advanced age and female sex as risk factors for high anion gap metabolic acidosis after a drug interaction between paracetamol and flucloxacillin: a case series
EA002435B1 (ru) Способ снижения уровня липопротеина (а) в сыворотке или в плазме крови млекопитающих
JP2005505605A (ja) 前痴呆状態におけるロスバスタチン
US20250325501A1 (en) A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia
EP1079852B1 (fr) Compositions a base de pentoxifylline et d' anticytokine
US20250248957A1 (en) Cell differentiation
US20250134867A1 (en) Method for modulating lipid metabolism, ameliorating non-alcoholic fatty liver disease and metabolic syndrome by using 6-methoxybenzoxazolinone
CN118286207A (zh) 药物组合物及卡格列净用于制备药物组合物的用途
Al‐kareem et al. A Comparative Study Between Atorvastatin and Pitavastatin Toxicity on Liver and Kidney in Albino Rats
RU2692243C1 (ru) Применение лактитола и пероральная лекарственная форма для лечения и профилактики неалкогольной жировой болезни печени
GB2638109A (en) Cell differentiation
Beatrice Anne et al. Chloroquine in the
Cuchel et al. Th-P16: 322 Microsomial transfer protein (MTP) inhibition substantially reduces cholesterol in patients with homozygous familial hypercholesterolemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant